Cangene has built its success on a 30-year history of developing, manufacturing and selling plasma-derived products, and remains one of the most consistent performers in the Canadian biopharmaceutical space. With commercial product sales dating back to 1980 and a Toronto Stock Exchange listing since 1991, we boast a history that few of our peers can match. Our product portfolio consists of purified, concentrated antibody preparations (hyperimmunes), with a focus on infectious disease, hematology, transplantation, and biodefense.
Four of our hyperimmune products are approved for use in the United States and/or Canada, as well as certain non-North American markets. We are focused on further expanding our commercial product pipeline through strategic acquisition s and licensing, as well as in-house development. Three of our products have been accepted into the U.S. Strategic National Stockpile.
Cangene’s business is divided into two operating segments: biopharmaceutical product sales and contract services. Our biopharmaceutical product segment comprises revenue from sales of our approved products and commercial sales of plasma collected at our plasma-collection centers. The contract-services segment includes revenues from our large government biodefense and commercial manufacturing contracts. Our Baltimore-based subsidiary, Cangene bioPharma, Inc., is responsible for contract manufacturing commercial product distribution.
Cangene has operations in Manitoba Canada, Pennsylvania and Maryland in the United States. The majority of our 600 employees work in the head office location in Winnipeg or in Baltimore at Cangene bioPharma.
Cangene is listed on the Toronto Stock Exchange under the symbol CNJ.